A Prospective Clinical Trial Evaluating PROSTest, a Blood-Based Molecular Assay, for Risk Stratification and Biopsy Decision Support in Men With Suspected Prostate Cancer

Part of paid clinical trials in Branford, Connecticut.

Sponsor
Wren Laboratories LLC
Study ID
NCT07454603
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
MALE
Age
45 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • PROSTEST — DIAGNOSTIC_TEST
    BLOOD SAMPLE FOR PROSTEST MEASUREMENT

Study Details

This prospective observational study will enroll men referred for prostate biopsy due to elevated PSA and/or abnormal digital rectal examination, with or without pre-biopsy MRI. Peripheral blood will be collected prior to biopsy for PROSTest analysis. Biopsy histopathology will serve as the reference standard. PROSTest results will be analyzed blinded to pathology.

Key Dates

Start date
Mar 15, 2026
Status verified
Mar 2026
Primary completion
Feb 28, 2027
Completion
Jun 1, 2027

Study Design

Enrollment
1,500 participants (estimated)

Primary Outcome Measure

Diagnostic accuracy of the PROSTest to detect prostate cancer at biopsy [ Time Frame: Following completion of the study. Study is anticipated to enroll over a year and be completed within 18 months. Samples will be evaluated at study end. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Wren LaboratoriesBranfordConnecticut06405
Mark Kidd, PhD
[email protected]
2038241128
Tracy Auster, BS
[email protected]
2032083464

Find similar trials in Branford, CT

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Wren Laboratories· Branford, CT

Related Studies